Trasturel 440mg Injection

Trasturel 440mg Injection contains Trustuzumab as an active ingredient which is a humanized monoclonal antibody. This medicine is prescribed to treat advanced and metastatic breast cancer and metastatic gastric cancer.

It works by inhibiting the action of HER2 receptor to control the multiplication and survival of cancer cells. This injection should be administered into the vein by a doctor or experienced nurse. Don't self- administer the injection.​

• Advanced and metastatic breast cancer
• Metastatic gastric cancer

Trasturel 440mg Injection is a strong anticancer medicine that may show certain adverse while manageable impact on the body during the treatment. As these effects resolve on their own without any special medical attention. However, if you ever experience serious or unusual side effects contact your healthcare professional immediately.

Some common side effects include:

• Headache
• Fatigue
• Neutropenia (Low white blood cells)
• Nausea and Vomiting
• Rash
• Diarrhea
• Infections
• Fever
• Infusion reactions (e.g., chills, fever, pain)
• Anaemia (Low red blood cells)

Serious Side Effects of Injection are:

• Congestive heart failure (CHF)
• Pulmonary toxicity (Lung issues)
• Cardiomyopathy (Heart dysfunction)
• Severe infusion reactions (e.g., difficulty breathing, low blood pressure)

• Trasturel 440mg Injection is a prescription-based anticancer drug.
• It is advised to take this injection after consulting your healthcare expert. This medicine should be given intravenously by an experienced nurse or doctor. Please do not self-administer.​​
  

• Trasturel 440mg Injection contains Trustuzumab as an active ingredient which is a humanized monoclonal antibody. It works by blocking the action of HER2 receptor that promote growth and survival of cancer cells in breast and gastric cancer.
• Thereby, by selectively binds to HER2 it controls or inhibit the growth & multiplication of cancer cells to slow down the progression of disease.​​
  

• Croxtall, J. D., & McKeage, K. (2010). Trastuzumab: in HER2-positive metastatic gastric cancer. Drugs, 70(17), 2259-2267. https://pubmed.ncbi.nlm.nih.gov/21080742/
• Bang, Y. J., Van Cutsem, E., Feyereislova, A., Chung, H. C., Shen, L., Sawaki, A., ... & Kang, Y. K. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. The Lancet, 376(9742), 687-697.https://pubmed.ncbi.nlm.nih.gov/20728210/
• Okines, A. F., & Cunningham, D. (2010). Trastuzumab in gastric cancer. European journal of cancer, 46(11), 1949-1959.
• Pohlmann, P. R., Mayer, I. A., & Mernaugh, R. (2009). Resistance to trastuzumab in breast cancer. Clinical cancer research, 15(24), 7479-7491.https://pubmed.ncbi.nlm.nih.gov/20008848/
• Maximiano, S., Magalhaes, P., Guerreiro, M. P., & Morgado, M. (2016). Trastuzumab in the treatment of breast cancer. BioDrugs, 30(2), 75-86.
• Cortés, J., Kim, S. B., Chung, W. P., Im, S. A., Park, Y. H., Hegg, R., ... & Hurvitz, S. A. (2022). Trastuzumab deruxtecan versus trastuzumab emtansine for breast cancer. New England Journal of Medicine, 386(12), 1143-1154.